سعر كادوميت 250 مجم 30 قرص 2022

Kadomet 250 mg tablets (methyldopa), 30-tablet pack, by Kahira Pharmaceuticals (Egypt).

• Hypertension.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Transient sedation, headache, asthenia or weakness early in therapy; others include orthostatic hypotension, oedema or weight gain, bradycardia, dry mouth, gastrointestinal upset, hyperprolactinaemia, haematological and hepatic reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active hepatic disease (e.g. acute hepatitis, active cirrhosis) or liver disorders previously associated with methyldopa.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to any component; patients on monoamine oxidase (MAO) inhibitors.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• A positive direct Coombs test develops in 10-20% of patients on prolonged therapy and may rarely be associated with haemolytic anaemia; liver disorders (hepatitis, jaundice) can occur, usually in the first 2-3 months; both can be fatal if not recognised.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Monoamine oxidase (MAO) inhibitorsConcomitant use is contraindicated.DailyMed (U.S. National Library of Medicine)

• No adequate well-controlled studies in the first trimester; use only if clearly needed. Published reports of use in all trimesters indicate the possibility of fetal harm appears remote, and controlled studies in hypertensive pregnant women showed improved fetal outcome.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Methyldopa appears in breast milk; use caution in nursing women.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Methyldopa: Metabolised to alpha-methylnorepinephrine, which stimulates central alpha-2 adrenergic receptors and reduces sympathetic outflow and peripheral resistance.